Viewing Study NCT05687266


Ignite Creation Date: 2025-12-24 @ 4:17 PM
Ignite Modification Date: 2026-01-02 @ 2:17 PM
Study NCT ID: NCT05687266
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-12-10
First Post: 2022-12-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module